Home › Trial NCT05185739
Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC)
- Trial IDNCT05185739
- StatusRecruiting
- PhasePhase 2
- Study typeInterventional
- SponsorUniversity College, London
- Enrollment60
- Start date2022-08-25
- ConditionsHepatocellular Carcinoma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.